Contact
searchSearch
HMP Global

Advertisement

Advertisement

ADVERTISEMENT

Lymphoma, Leukemia & Myeloma Network

Featured

Amrita Krishnan, MD
Videos
Should Autologous Stem Cell Transplantation be Considered for Older Patients With Multiple Myeloma?  
07/28/2024
At the 2024 Great Debates & Updates meeting, Amrita Krishnan, MD, argued for the value of considering autologous stem cell transplantation for certain patients over the age of 65, emphasizing the benefit of assessing frailty as a complex and...
At the 2024 Great Debates & Updates meeting, Amrita Krishnan, MD, argued for the value of considering autologous stem cell transplantation for certain patients over the age of 65, emphasizing the benefit of assessing frailty as a complex and...
At the 2024 Great Debates &...
07/28/2024
Oncology
From Oncology
Murali Janakiram, MD, MS
Videos
Should Minimal Residual Disease Guide Therapy for Patients With Multiple Myeloma?
07/28/2024
At the 2024 Great Debates & Updates meeting, Murali Janakiram, MD, MS, participated in a debate about the value of MRD assessment in the treatment and management of multiple myeloma.
At the 2024 Great Debates & Updates meeting, Murali Janakiram, MD, MS, participated in a debate about the value of MRD assessment in the treatment and management of multiple myeloma.
At the 2024 Great Debates &...
07/28/2024
Oncology
From Oncology
Inhye Ahn, MD
Videos
Assessing the Impact of FDA Approval of Pirtobrutinib in the R/R Chronic Lymphocytic Leukemia Treatment Landscape
07/28/2024
Inhye Ahn, MD, shares insight into the real-world practice impact of the FDA approval of non-covalent Bruton tyrosine kinase inhibitor pirtobrutinib for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have...
Inhye Ahn, MD, shares insight into the real-world practice impact of the FDA approval of non-covalent Bruton tyrosine kinase inhibitor pirtobrutinib for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have...
Inhye Ahn, MD, shares insight...
07/28/2024
Lymphoma, Leukemia & Myeloma Network
Inhye Ahn, MD
Videos
Investigating Next Steps for Pirtobrutinib Therapy Among Patients With Chronic Lymphocytic Leukemia
07/28/2024
Inhye Ahn, MD, discusses next steps for investigating applications of pirtobrutinib in the current treatment paradigm for patients with chronic lymphocytic leukemia.
Inhye Ahn, MD, discusses next steps for investigating applications of pirtobrutinib in the current treatment paradigm for patients with chronic lymphocytic leukemia.
Inhye Ahn, MD, discusses next...
07/28/2024
Lymphoma, Leukemia & Myeloma Network
Tycel Phillips, MD
Videos
Novel Developments in the Frontline and Relapsed/Refractory Mantle Cell Lymphoma Treatment Landscape
07/28/2024
Tycel Phillips, MD, reviews the latest updates and developments in both the frontline and relapsed/refractory treatment landscape for patients with mantle cell lymphoma.
Tycel Phillips, MD, reviews the latest updates and developments in both the frontline and relapsed/refractory treatment landscape for patients with mantle cell lymphoma.
Tycel Phillips, MD, reviews the...
07/28/2024
Lymphoma, Leukemia & Myeloma Network
Tycel Phillips, MD
Videos
Exploring Non-Chemotherapy Options for the Frontline Treatment of Patients With Mantle Cell Lymphoma
07/28/2024
At the 2024 Great Debates & Updates meeting, Tycel Phillips, MD, participated in a debate about the role of non-chemotherapy regimens for the treatment of patients with newly diagnosed mantle cell lymphoma.
At the 2024 Great Debates & Updates meeting, Tycel Phillips, MD, participated in a debate about the role of non-chemotherapy regimens for the treatment of patients with newly diagnosed mantle cell lymphoma.
At the 2024 Great Debates &...
07/28/2024
Lymphoma, Leukemia & Myeloma Network
News
Venetoclax Monotherapy Demonstrates Deep, Durable Responses Among Adult Patients With R/R CLL
07/10/2024
According to phase 3b results from the VENICE-1 trial, venetoclax monotherapy demonstrates durable responses in adult patients with relapsed/refractory chronic lymphocytic leukemia, including B-cell receptor-associated kinase inhibitor...
According to phase 3b results from the VENICE-1 trial, venetoclax monotherapy demonstrates durable responses in adult patients with relapsed/refractory chronic lymphocytic leukemia, including B-cell receptor-associated kinase inhibitor...
According to phase 3b results...
07/10/2024
Lymphoma, Leukemia & Myeloma Network
Michael Wang, MD
Videos
Ibrutinib Plus Venetoclax Demonstrates Efficacy, Safety for TP53-Mutated Mantle Cell Lymphoma Treatment
07/09/2024
Michael Wang, MD, presents data from the SYMPATICO trail on the encouraging efficacy and safety of ibrutinib plus venetoclax for patients with high-risk TP53-mutated mantle cell lymphoma.
Michael Wang, MD, presents data from the SYMPATICO trail on the encouraging efficacy and safety of ibrutinib plus venetoclax for patients with high-risk TP53-mutated mantle cell lymphoma.
Michael Wang, MD, presents data...
07/09/2024
Lymphoma, Leukemia & Myeloma Network
Quiz
Efficacy of Rituximab Maintenance After ASCT Among Patients With Mantle Cell Lymphoma
07/09/2024
True or False: According to a 7.5-year follow-up of the LYMA trial, standard-of-care therapy of rituximab maintenance following autologous stem cell transplantation continued to demonstrate benefits to efficacy and safety outcomes among...
True or False: According to a 7.5-year follow-up of the LYMA trial, standard-of-care therapy of rituximab maintenance following autologous stem cell transplantation continued to demonstrate benefits to efficacy and safety outcomes among...
True or False: According to a...
07/09/2024
Lymphoma, Leukemia & Myeloma Network
News
FDA Approval of Lisocabtagene Maraleucel for Patients With R/R Mantle Cell Lymphoma
07/09/2024
The U.S. Food and Drug Administration granted approval to lisocabtagene maraleucel for adult patients with relapsed or refractory MCL who have received at least 2 prior lines of systemic therapy including a BTK inhibitor.
The U.S. Food and Drug Administration granted approval to lisocabtagene maraleucel for adult patients with relapsed or refractory MCL who have received at least 2 prior lines of systemic therapy including a BTK inhibitor.
The U.S. Food and Drug...
07/09/2024
Lymphoma, Leukemia & Myeloma Network
Moritz Furstenau, MD
Conference Coverage
Efficacy and ctDNA Analysis of MRD-Guided Acalabrutinib, Venetoclax, and Obinutuzumab for Patients With R/R CLL
06/26/2024

Featuring Moritz Furstenau, MD

Featuring Moritz Furstenau, MD ...
At the 65th ASH Annual Meeting, Moritz Furstenau, MD, presented a follow-up analysis of the CLL2-Baag trial on the efficacy and ctDNA analysis of acalabrutinib, venetoclax, and obinutuzumab combination therapy after optional debulking with...
At the 65th ASH Annual Meeting, Moritz Furstenau, MD, presented a follow-up analysis of the CLL2-Baag trial on the efficacy and ctDNA analysis of acalabrutinib, venetoclax, and obinutuzumab combination therapy after optional debulking with...
At the 65th ASH Annual Meeting,...
06/26/2024
Oncology
From Oncology

Advertisement

Interactive Features

Quiz
Efficacy of Rituximab Maintenance After ASCT Among Patients With Mantle Cell Lymphoma
07/09/2024
True or False: According to a 7.5-year follow-up of the LYMA trial, standard-of-care therapy of rituximab maintenance following autologous stem cell transplantation continued to demonstrate benefits to efficacy and safety outcomes among...
True or False: According to a 7.5-year follow-up of the LYMA trial, standard-of-care therapy of rituximab maintenance following autologous stem cell transplantation continued to demonstrate benefits to efficacy and safety outcomes among...
True or False: According to a...
07/09/2024
Lymphoma, Leukemia & Myeloma Network
Quiz
Overall Response Rate of Tafasitamab Plus Lenalidomide for Patients With R/R Diffuse Large B-Cell Lymphoma
06/14/2023
Quiz: According to final results of the phase 2 L-MIND study, what was the overall response rate of tafasitamab plus lenalidomide followed by long-term tafasitamab monotherapy for patients with R/R diffuse large B-cell lymphoma?
Quiz: According to final results of the phase 2 L-MIND study, what was the overall response rate of tafasitamab plus lenalidomide followed by long-term tafasitamab monotherapy for patients with R/R diffuse large B-cell lymphoma?
Quiz: According to final results...
06/14/2023
Oncology
Quiz
Radiomics Features and Prediction of Outcomes for Aggressive B-Cell Lymphoma
06/09/2023
True or False In a study assessing the predictive quality of clinical, molecular genotype, and radiomics features for aggressive B-cell lymphoma, results indicated that radiomics features extracted from baseline 18F-FDG PET/CT scans...
True or False In a study assessing the predictive quality of clinical, molecular genotype, and radiomics features for aggressive B-cell lymphoma, results indicated that radiomics features extracted from baseline 18F-FDG PET/CT scans...
True or False In a study...
06/09/2023
Oncology

Insights

Amrita Krishnan, MD
Videos
Should Autologous Stem Cell Transplantation be Considered for Older Patients With Multiple Myeloma?  
07/28/2024
At the 2024 Great Debates & Updates meeting, Amrita Krishnan, MD, argued for the value of considering autologous stem cell transplantation for certain patients over the age of 65, emphasizing the benefit of assessing frailty as a complex and...
At the 2024 Great Debates & Updates meeting, Amrita Krishnan, MD, argued for the value of considering autologous stem cell transplantation for certain patients over the age of 65, emphasizing the benefit of assessing frailty as a complex and...
At the 2024 Great Debates &...
07/28/2024
Oncology
Murali Janakiram, MD, MS
Videos
Should Minimal Residual Disease Guide Therapy for Patients With Multiple Myeloma?
07/28/2024
At the 2024 Great Debates & Updates meeting, Murali Janakiram, MD, MS, participated in a debate about the value of MRD assessment in the treatment and management of multiple myeloma.
At the 2024 Great Debates & Updates meeting, Murali Janakiram, MD, MS, participated in a debate about the value of MRD assessment in the treatment and management of multiple myeloma.
At the 2024 Great Debates &...
07/28/2024
Oncology
Inhye Ahn, MD
Videos
Assessing the Impact of FDA Approval of Pirtobrutinib in the R/R Chronic Lymphocytic Leukemia Treatment Landscape
07/28/2024
Inhye Ahn, MD, shares insight into the real-world practice impact of the FDA approval of non-covalent Bruton tyrosine kinase inhibitor pirtobrutinib for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have...
Inhye Ahn, MD, shares insight into the real-world practice impact of the FDA approval of non-covalent Bruton tyrosine kinase inhibitor pirtobrutinib for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have...
Inhye Ahn, MD, shares insight...
07/28/2024
Lymphoma, Leukemia & Myeloma Network
Inhye Ahn, MD
Videos
Investigating Next Steps for Pirtobrutinib Therapy Among Patients With Chronic Lymphocytic Leukemia
07/28/2024
Inhye Ahn, MD, discusses next steps for investigating applications of pirtobrutinib in the current treatment paradigm for patients with chronic lymphocytic leukemia.
Inhye Ahn, MD, discusses next steps for investigating applications of pirtobrutinib in the current treatment paradigm for patients with chronic lymphocytic leukemia.
Inhye Ahn, MD, discusses next...
07/28/2024
Lymphoma, Leukemia & Myeloma Network
Tycel Phillips, MD
Videos
Novel Developments in the Frontline and Relapsed/Refractory Mantle Cell Lymphoma Treatment Landscape
07/28/2024
Tycel Phillips, MD, reviews the latest updates and developments in both the frontline and relapsed/refractory treatment landscape for patients with mantle cell lymphoma.
Tycel Phillips, MD, reviews the latest updates and developments in both the frontline and relapsed/refractory treatment landscape for patients with mantle cell lymphoma.
Tycel Phillips, MD, reviews the...
07/28/2024
Lymphoma, Leukemia & Myeloma Network
Tycel Phillips, MD
Videos
Exploring Non-Chemotherapy Options for the Frontline Treatment of Patients With Mantle Cell Lymphoma
07/28/2024
At the 2024 Great Debates & Updates meeting, Tycel Phillips, MD, participated in a debate about the role of non-chemotherapy regimens for the treatment of patients with newly diagnosed mantle cell lymphoma.
At the 2024 Great Debates & Updates meeting, Tycel Phillips, MD, participated in a debate about the role of non-chemotherapy regimens for the treatment of patients with newly diagnosed mantle cell lymphoma.
At the 2024 Great Debates &...
07/28/2024
Lymphoma, Leukemia & Myeloma Network
Michael Wang, MD
Videos
Ibrutinib Plus Venetoclax Demonstrates Efficacy, Safety for TP53-Mutated Mantle Cell Lymphoma Treatment
07/09/2024
Michael Wang, MD, presents data from the SYMPATICO trail on the encouraging efficacy and safety of ibrutinib plus venetoclax for patients with high-risk TP53-mutated mantle cell lymphoma.
Michael Wang, MD, presents data from the SYMPATICO trail on the encouraging efficacy and safety of ibrutinib plus venetoclax for patients with high-risk TP53-mutated mantle cell lymphoma.
Michael Wang, MD, presents data...
07/09/2024
Lymphoma, Leukemia & Myeloma Network
Moritz Furstenau, MD
Conference Coverage
Efficacy and ctDNA Analysis of MRD-Guided Acalabrutinib, Venetoclax, and Obinutuzumab for Patients With R/R CLL
06/26/2024

Featuring Moritz Furstenau, MD

Featuring Moritz Furstenau, MD ...
At the 65th ASH Annual Meeting, Moritz Furstenau, MD, presented a follow-up analysis of the CLL2-Baag trial on the efficacy and ctDNA analysis of acalabrutinib, venetoclax, and obinutuzumab combination therapy after optional debulking with...
At the 65th ASH Annual Meeting, Moritz Furstenau, MD, presented a follow-up analysis of the CLL2-Baag trial on the efficacy and ctDNA analysis of acalabrutinib, venetoclax, and obinutuzumab combination therapy after optional debulking with...
At the 65th ASH Annual Meeting,...
06/26/2024
Oncology
Samantha Shenoy
Videos
Management Considerations for Oral Toxicities Associated With Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma
05/10/2024
Samantha Shenoy, NP, discusses considerations for nurses and advanced practitioners managing patients with relapsed/refractory multiple myeloma experiencing oral toxicities after treatment with talquetamab.
Samantha Shenoy, NP, discusses considerations for nurses and advanced practitioners managing patients with relapsed/refractory multiple myeloma experiencing oral toxicities after treatment with talquetamab.
Samantha Shenoy, NP, discusses...
05/10/2024
Lymphoma, Leukemia & Myeloma Network
John Allan, MD, Weill Cornell Medicine
Conference Coverage
Comparing BTK Inhibitors for Frontline Chronic Lymphocytic Leukemia Treatment
04/19/2024

Featuring John Allan, MD

Featuring John Allan, MD
John Allan, MD, compares the use of different BTK inhibitors for the treatment of CLL in a frontline setting and discusses whether there is an optimal drug regimen to use among patients with CLL.
John Allan, MD, compares the use of different BTK inhibitors for the treatment of CLL in a frontline setting and discusses whether there is an optimal drug regimen to use among patients with CLL.
John Allan, MD, compares the use...
04/19/2024
Lymphoma, Leukemia & Myeloma Network

Meeting Materials

The Tree That Hides the Forest: An Unfortunate Story of T/NK Lymphoma
Introduction: NK/T lymphoma is a rare type of non-Hodgkin's lymphoma [1,2]. It is a clinical entity that manifests itself essentially by a necrosis that usually starts in the nasal caviti...
11/04/2022
Real-world Experience with Isatuximab in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): IONA-MM First Interim Analysis
Introduction:
11/04/2022
Developing an Ontology-Based Platform to Detect Serine Protease Involvement in BALT Lymphoma Patients with COVID-19 & Connect Them to Clinical Trials
Introduction:
11/04/2022

Advertisement

Advertisement

In the News

News
Venetoclax Monotherapy Demonstrates Deep, Durable Responses Among Adult Patients With R/R CLL
07/10/2024
According to phase 3b results from the VENICE-1 trial, venetoclax monotherapy demonstrates durable responses in adult patients with relapsed/refractory chronic lymphocytic leukemia, including B-cell receptor-associated kinase inhibitor...
According to phase 3b results from the VENICE-1 trial, venetoclax monotherapy demonstrates durable responses in adult patients with relapsed/refractory chronic lymphocytic leukemia, including B-cell receptor-associated kinase inhibitor...
According to phase 3b results...
07/10/2024
Lymphoma, Leukemia & Myeloma Network
News
FDA Approval of Lisocabtagene Maraleucel for Patients With R/R Mantle Cell Lymphoma
07/09/2024
The U.S. Food and Drug Administration granted approval to lisocabtagene maraleucel for adult patients with relapsed or refractory MCL who have received at least 2 prior lines of systemic therapy including a BTK inhibitor.
The U.S. Food and Drug Administration granted approval to lisocabtagene maraleucel for adult patients with relapsed or refractory MCL who have received at least 2 prior lines of systemic therapy including a BTK inhibitor.
The U.S. Food and Drug...
07/09/2024
Lymphoma, Leukemia & Myeloma Network
News
Circulating Tumor DNA Monitoring for Patients With Follicular Lymphoma Undergoing CAR T-Cell Therapy
06/26/2023

Jordan Kadish 

Jordan Kadish 
Circulating tumor DNA monitoring demonstrated efficacy as a non-invasive method in correlating treatment responses and monitoring disease progression among patients with follicular lymphoma undergoing CAR T-cell therapy.
Circulating tumor DNA monitoring demonstrated efficacy as a non-invasive method in correlating treatment responses and monitoring disease progression among patients with follicular lymphoma undergoing CAR T-cell therapy.
Circulating tumor DNA monitoring...
06/26/2023
Oncology
News
Efficacy and Safety of Rituximab-Bendamustine vs R-CHOP Among Patients With Follicular Lymphoma
06/26/2023

Jordan Kadish

Jordan Kadish
Rituximab-bendamustine and R-CHOP yielded similar efficacy results, but had distinct safety profiles and long-term events among patients with follicular lymphoma.
Rituximab-bendamustine and R-CHOP yielded similar efficacy results, but had distinct safety profiles and long-term events among patients with follicular lymphoma.
Rituximab-bendamustine and...
06/26/2023
Oncology
News
FDA Grants Accelerated Approval to Glofitamab for Patients With R/R Diffuse Large B-Cell Lymphoma
06/23/2023

Jordan Kadish

Jordan Kadish
On June 15, 2023, the FDA granted accelerated approval to glofitamab-gxbm for the treatment of patients with relapsed/refractory DLBCL, not otherwise specified, or large B-cell lymphoma arising from follicular lymphoma after ≥ 2 lines of...
On June 15, 2023, the FDA granted accelerated approval to glofitamab-gxbm for the treatment of patients with relapsed/refractory DLBCL, not otherwise specified, or large B-cell lymphoma arising from follicular lymphoma after ≥ 2 lines of...
On June 15, 2023, the FDA...
06/23/2023
Oncology
News
Brentuximab Vedotin Plus Doxorubicin and Dacarbazine for Patients With Nonbulky Limited-Stage Classic Hodgkin Lymphoma
06/23/2023

Jordan Kadish

Jordan Kadish
Results from a phase 2 study indicated that brentuximab vedotin plus doxorubicin and dacarbazine combination treatment showed promise as a treatment for patients with limited-stage classical Hodgkin lymphoma.
Results from a phase 2 study indicated that brentuximab vedotin plus doxorubicin and dacarbazine combination treatment showed promise as a treatment for patients with limited-stage classical Hodgkin lymphoma.
Results from a phase 2 study...
06/23/2023
Oncology
News
Clinical Outcomes After BTK Inhibitor and B-Cell Lymphoma 2 Inhibitor Treatment Among Patients With CLL
06/08/2023

Jordan Kadish

Jordan Kadish
The real-world response rates among patients with CLL/SLL after receiving covalent BTK inhibitor and B-cell lymphoma 2 inhibitor treatment demonstrate a need for more effective follow-up therapies, according to a retrospective real-world...
The real-world response rates among patients with CLL/SLL after receiving covalent BTK inhibitor and B-cell lymphoma 2 inhibitor treatment demonstrate a need for more effective follow-up therapies, according to a retrospective real-world...
The real-world response rates...
06/08/2023
Oncology
News
Ki67 Expression Shows Promise as a Predictive Marker for Follicular Lymphoma
06/08/2023

Jordan Kadish

Jordan Kadish
High follicular Ki67 expression was associated with longer progression-free survival among patients with follicular lymphoma who were treated with R-CHOP immunochemotherapy, suggesting its potential as a predictive marker.
High follicular Ki67 expression was associated with longer progression-free survival among patients with follicular lymphoma who were treated with R-CHOP immunochemotherapy, suggesting its potential as a predictive marker.
High follicular Ki67 expression...
06/08/2023
Oncology

Advertisement

Latest Podcasts

Podcasts
Dr Leonard Shares Highlights to Expect at the 2020 Lymphoma, Leukemia & Myeloma Congress
10/19/2020
John Leonard, MD, discusses what to expect at the virtual 2020 Lymphoma, Leukemia & Myeloma Congress taking place October 21-24, 2020.
John Leonard, MD, discusses what to expect at the virtual 2020 Lymphoma, Leukemia & Myeloma Congress taking place October 21-24, 2020.
John Leonard, MD, discusses what...
10/19/2020
Oncology
What to Expect at the Non-Malignant Hematology Workshop at Lymphoma, Leukemia & Myeloma Congress
Podcasts
What to Expect at the Non-Malignant Hematology Workshop at Lymphoma, Leukemia & Myeloma Congress
08/24/2020
James B. Bussel, MD, gives an overview of what to expect at the brand new Non-Malignant Hematology Workshop and how the content is critical for hematology and oncology practice.
James B. Bussel, MD, gives an overview of what to expect at the brand new Non-Malignant Hematology Workshop and how the content is critical for hematology and oncology practice.
James B. Bussel, MD, gives an...
08/24/2020
Oncology
Podcasts
Seattle Children's Hospital Leukemia Program Offers Multidisciplinary Care to Underserved Population
06/19/2018
Todd Cooper, DO, discusses a new program launched at The Seattle Children's Hospital for patients with high-risk leukemia.
Todd Cooper, DO, discusses a new program launched at The Seattle Children's Hospital for patients with high-risk leukemia.
Todd Cooper, DO, discusses a new...
06/19/2018
Oncology

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use